Igniting our potential

UK Health Research Analysis 2014

UK Health Research Analyses

• UKCRC established the Health Research Classification System in 2004

• HRAF (12 of the largest public and charitable health research funders + AMRC)

• Analysis of UK health research based on HRAF research portfolio carried out in 2004/05, and 2009/10

• Repeat analysis in 2014, to provide 10 year picture of expenditure on health research in the UK

Research Analysis Total Spend

  2004/05 2009/10 2014(HRAF)

2014(All)

Participating organisations 12 12 12 64

Number of awards coded 9,901 11,482 12,696 14,934

Value of awards coded (£bn)(real terms) 1.19 1.77 1.90 2.03

Value of infrastructure funding (£m) (real terms) N/A 895 952 984

2004/05 2009/10 2014£0.0bn

£0.5bn

£1.0bn

£1.5bn

£2.0bn

£2.5bn

£1.19bn

£1.77bn £1.90bn

£2.03bnHRAF New Funders

HRCS Research Activities 2014

459500951.5020823%

593805706.99492329%

105638535.92585%

206633105.84068810%

264071222.52966413%

196218491.610%

80948170.10539564%

118229269.7486756%

1 Underpinning

2 Aetiology

3 Prevention

4 Detection and Diagnosis

5 Treatment Development

6 Treatment Evaluation

7 Disease Management

8 Health Services

Changes in Research Activity 2004-2014

HRCS Health Categories 2014

Generic Health Relevance - £477m (24%)

Cancer - £402m (20%)

Infection - £227m (11%)

Neurological - £194m (10%)

Cardiovascular - £139m (7%)

Mental Health - £112m (5%)

Inflammatory - £86m (4%)

Metabolic - £60m (3%)

Musculoskeletal - £59m (3%)

Reproduction - £48m (2%)

REMAINDER - £220m (11%)(11 categories, <2% each)

Changes in Health Category 2004-2014

Injuries and Accidents

Ear

Blood

Other

Congenital Disorders

Skin

Renal and Urogenital

Eye

Stroke

Respiratory

Oral and Gastrointestinal

Reproductive Health and Childbirth

Metabolic and Endocrine

Musculoskeletal

Inflammatory and Immune System

Mental Health

Cardiovascular

Neurological

Infection

Cancer

Generic Health Relevance

0% 5% 10% 15% 20% 25% 30%

2004/05

2009/10

2014 (HRAF)

Burden of Disease Comparison

Injuries and Accidents

Skin

Congenital Disorders

Reproductive Health and Childbirth

Ear / Eye

Metabolic and Endocrine

Renal and Urogenital

Infection

Oral and Gastrointestinal

Neurological

Respiratory

Musculoskeletal

Mental Health

Blood / Cardiovascular / Stroke

Cancer

0% 2% 4% 6% 8% 10% 12% 14% 16% 18% 20%

Proportion of 2014 spend (64 funders)

UK DALY rate (2012)

HRCS Geographic Distribution 2014

Dundee 2.3%

Edinburgh 4.5%

Newcastle Upon Tyne 2.4%

Leeds 1.9%

Sheffield 1.6%

Nottingham 2.3%

Leicester 1.2%

Cambridge 12.1%

Oxford 10.7%

London 32.1%

Southampton 0.7%

12.8%

3.7%

2.9%

6.1%

0.8%

11.8%

15.8%3.7%

2.5%

3.4%

4.5%

Glasgow 3.5%

Belfast 0.7%

Manchester 3.9%

Birmingham 2.3%

Cardiff 1.7%

Bristol 2.7%

Liverpool 1.9%

Changes in UK Distribution 2004-2014

East A

nglia

East M

idla

nds

Lond

onNor

th

North

Wes

t

North

ern

Irela

nd

Scotla

nd

South

Eas

t

South

Wes

t

Wal

es

Wes

t Mid

land

s

Yorks

/ Hum

bers

ide

0%

5%

10%

15%

20%

25%

30%

35%

2004/05

2009/10

2014 (HRAF)

HRCS Sector Distribution 2014 (RA)

1 Under-pinning

2 Aetiology 3 Prevention 4 Detection and Diag-

nosis

5 Treatment Develop-

ment

6 Treatment Evaluation

7 Disease Management

8 Health Services

£m

£100m

£200m

£300m

£400m

£500m

£600m

RCUK Charity Government

HRCS Sector Distribution 2014 (HC)

Inflammatory and Immune System

Mental Health

Cardiovascular

Neurological

Infection

Cancer

Generic Health Relevance

£m £100m £200m £300m £400m £500m £600m

Injuries and AccidentsEar

SkinCongenital Disorders

BloodOther

Renal and UrogenitalEye

StrokeRespiratory

Oral and GastrointestinalReproductive Health and Childbirth

MusculoskeletalMetabolic and Endocrine

£m £10m £20m £30m £40m £50m £60m £70m

Government

Charity

RCUK

Overall UK health research spend

• UK Health Research Analysis ‘bottom up’ assessment vs. total UK health relevant expenditure ‘top down’ estimate

• 2014 Analysis showed a combined spend (direct research + infrastructure) of £3.01bn

• Estimation of funding from additional sources adds a further £1bn• Comparison with total UK health research expenditure estimate (£8.5bn)

shows ~47% of all UK health research expenditure accounted for.• Comparison with estimation in 2009/10 shows UK health research spending

shrank by £780m, largely from decrease in pharmaceutical industry expenditure.

Performing Sector 2009/10 (£bn)(real terms) 2013/14 (£bn) Difference

(£m)

Business 4.8 4.1 -700

Private non-Profit (PNP) 0.4 0.4 +10

University 2.5 2.7 +210

Public SectorResearch Institutes 1.6 1.3 -300

TOTAL 9.3 8.5 -780